The Nanoparticle Development, Production and Characterization Core (NP Core) will provide well characterized nanoparticles for all four projects associated with the Dartmouth CCNE. During the start-up phase of the CCNE, we will acquire commercial dextran-coated superparamagnefic iron oxide nanoparticles (SPIOs) from Aspens Systems, Inc., Mariborough, MA (see supporting letter). These will be used initially in all the projects to jumpstart them. Forthe purposes of quality control, the core will measure both the magnetic properties and heating behavior in an applied alternating magnetic field for all the SPIOs that we will use. The main purpose ofthe core is to provide biocompatibly-coated magnetic iron/iron oxide core/shell nanocomposite particles (mNPs) that have been developed at Dartmouth. These mNPs, which have superior heating characteristics to SPIOs, will be produced with a variety of sizes (8-100 nm) as requested by each of the projects. The mNPs will be made through our well-established microemulsion techniques and a biocompatible coating of either a phospholipid or dextran and polyethylene glycol (as required by different projects) will then be assembled onto the mNPs. Transmission electron microscopy will be used to characterize the nanoparticle size and size distribution;a vibrating sample magnetometer will be used to measure the magnetic properties of the mNPs in an alternating magnefic field (for quality control);and the heating effect of the mNPs will also be measured (again for quality control). Statistical analysis of the measurements of nanoparticle size measurements, magnetic measurements and heating measurements will be performed by the Biostatistics, Data Analysis and Computational Core. Advances that will be required in the NP Core as the work progresses include the development a wider range of particle sizes (currently only 8-20 nm have been produced);and scale up of the producfion of the mNPs to produce larger quantities will be needed.
The NP Core will provide novel, well-characterized, biocompatible magnetic nanoparticles that can be heated in an alternating magnetic field to destroy tumors. The use of these nanoparticles inifially will be for breast cancer and ovarian cancer treatment, but the nanoparticles can potentially be used for any type of cancer.
|Ficko, Bradley W; NDong, Christian; Giacometti, Paolo et al. (2017) A Feasibility Study of Nonlinear Spectroscopic Measurement of Magnetic Nanoparticles Targeted to Cancer Cells. IEEE Trans Biomed Eng 64:972-979|
|Hoopes, P Jack; Moodie, Karen L; Petryk, Alicia A et al. (2017) Hypo-fractionated Radiation, Magnetic Nanoparticle Hyperthermia and a Viral Immunotherapy Treatment of Spontaneous Canine Cancer. Proc SPIE Int Soc Opt Eng 10066:|
|Pearce, John A; Petryk, Alicia A; Hoopes, P Jack (2017) Numerical Model Study of In Vivo Magnetic Nanoparticle Tumor Heating. IEEE Trans Biomed Eng 64:2813-2823|
|Hoopes, P Jack; Mazur, Courtney M; Osterberg, Bjorn et al. (2017) Effect of intra-tumoral magnetic nanoparticle hyperthermia and viral nanoparticle immunogenicity on primary and metastatic cancer. Proc SPIE Int Soc Opt Eng 10066:|
|Tesone, Amelia J; Rutkowski, Melanie R; Brencicova, Eva et al. (2016) Satb1 Overexpression Drives Tumor-Promoting Activities in Cancer-Associated Dendritic Cells. Cell Rep 14:1774-1786|
|Reeves, Daniel B; Shi, Yipeng; Weaver, John B (2016) Generalized Scaling and the Master Variable for Brownian Magnetic Nanoparticle Dynamics. PLoS One 11:e0150856|
|Lizotte, P H; Wen, A M; Sheen, M R et al. (2016) In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. Nat Nanotechnol 11:295-303|
|Sheen, M R; Marotti, J D; Allegrezza, M J et al. (2016) Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer. Oncogenesis 5:e267|
|Kekalo, Katsiaryna; Shubitidze, Fridon; Meyers, Robert et al. (2016) Magnetic Heating of Fe-Co Ferrites: Experiments and Modeling. Nano Life 6:|
|Allegrezza, Michael J; Rutkowski, Melanie R; Stephen, Tom L et al. (2016) IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors. Cancer Res 76:2561-72|
Showing the most recent 10 out of 107 publications